Bioluminescence resonance energy transfer as a screening assay: Focus on partial and inverse agonism

Journal of Biomolecular Screening

Volumn 12, Issue 1, 2007, Pages 41-49

  Elster, Lisbeth ^a,b   Elling, Christian ^a   Heding, Anders ^a  

^a 7TM Pharma A S   (Denmark)

^b 7TM Pharma ^*  (Denmark)

Author keywords

2 adrenergic receptor; BRET assay; cAMP assay; Constitutive activity; Inverse agonism; Partial agonism

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; ADRENALIN; ALPRENOLOL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ARRESTIN 2; CYCLIC AMP; DOBUTAMINE; DOPAMINE; EPHEDRINE; FENOTEROL; FORMOTEROL; ISOPRENALINE; NORADRENALIN; PINDOLOL; PROPRANOLOL; SALBUTAMOL; SALMETEROL; TERBUTALINE;

ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DETERMINATION; DRUG MECHANISM; DRUG SCREENING; EMBRYO; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL;

ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ALBUTEROL; ANIMALS; CERCOPITHECUS AETHIOPS; COS CELLS; CYCLIC AMP; ENERGY TRANSFER; HUMANS; ISOPROTERENOL; RECEPTORS, ADRENERGIC, BETA-2; SPECTROMETRY, FLUORESCENCE;

EID: 33846870553     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057106295895     Document Type: Article

References (25)

1. Hemmila IA, Hurskainen P: Novel detection strategies for drug discovery. Drug Discov Today 2002 ; 7: S150 - S156.
2. Kostenis E: Is Galpha16 the optimal tool for fishing ligands of orphan G-protein-coupled receptors? Trends Pharmacol Sci 2001 ; 22: 560-564.
3. Angers S, Salahpour A, Bouvier M: Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function. Annu Rev Pharmacol Toxicol 2002 ; 42: 409-435.
4. Azzi M, Charest PG, Angers S, Rousseau G, Kohout T, Bouvier M,, et al. β-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci U S A 2003 ; 100: 11406-11411.
5. Vrecl M, Jorgensen R, Pogacnik A, Heding A: Development of a BRET2 screening assay using β-arrestin 2 mutants. J Biomol Screen 2004 ; 9: 322-333.
6. Claing A, Laporte SA, Caron MG, Lefkowitz RJ: Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and β-arrestin proteins. Prog Neurobiol 2002 ; 66: 61-79.
7. Perry SJ, Lefkowitz RJ: Arresting developments in heptahelical receptor signaling and regulation. Trends Cell Biol 2002 ; 2: 130-138.
8. Lefkowitz RJ: G protein-coupled receptors. III. New roles for receptor kinases and β-arrestins in receptor signaling and desensitization. J Biol Chem 1998 ; 273: 18677-18680.
9. Luttrell LM, Lefkowitz RJ: The role of β-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci 2002 ; 115: 455-465.
10. Luttrell LM: "Location, location, location": activation and targeting of MAP kinases by G protein-coupled receptors. J Mol Endocrinol 2003 ; 30: 117-126.
11. Oakley RH, Laporte SA, Holt JA, Caron MG, Barak LS: Differential affinities of visual arrestin, β arrestin1, and β arrestin2 for G protein-coupled receptors delineate two major classes of receptors. J Biol Chem 2000 ; 275: 17201-17210.
12. Boute N, Jockers R, Issad T: The use of resonance energy transfer in high-throughput screening: BRET versus FRET. Trends Pharmacol Sci 2002 ; 23: 351-354.
13. Heding A: Use of the BRET 7TM receptor/β-arrestin assay in drug discovery and screening. Expert Rev Mol Diagn 2004 ; 4: 403-411.
14. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN: Comparative pharmacology of human β-adrenergic receptor subtypes - characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol 2004 ; 369: 151-159.
15. Guimaraes S, Moura D: Vascular adrenoceptors: an update. Pharmacol Rev 2001 ; 53: 319-356.
16. Kotlikoff MI, Kamm KE: Molecular mechanisms of β-adrenergic relaxation of airway smooth muscle. Annu Rev Physiol 1996 ; 58: 115-141.
17. Swaminath G, Xiang Y, Lee TW, Steenhuis J, Parnot C, Kobilka BK: Sequential binding of agonists to the β2 adrenoceptor: kinetic evidence for intermediate conformational states. J Biol Chem 2004 ; 279: 686-691.
18. van der Woude HJ, Aalbers R: Long-acting β2-agonists: comparative pharmacology and clinical outcomes. Am J Respir Med 2002 ; 1: 55-74.
19. Oakley RH, Hudson CC, Cruickshank RD, Meyers DM, Payne RE, Rhem SM,, et al. The cellular distribution of fluorescently labeled arrestins provides a robust, sensitive, and universal assay for screening G protein-coupled receptors. Assay Drug Dev Technol 2002 ; 1: 21-30.
20. Jorgensen J, Martini L, Schwartz TW, Elling CE: Characterization of glucagon-like peptide-1 receptor β-arrestin2 interaction: a high-affinity receptor phenotype. Mol Endocrinol 2005 ; 19: 812-823.
21. McGraw DW, Liggett SB: Heterogeneity in β-adrenergic receptor kinase expression in the lung accounts for cell-specific desensitization of the β2-adrenergic receptor. J Biol Chem 1997 ; 272: 7338-7344.
22. Tran TM, Friedman J, Qunaibi E, Baameur F, Moore RH, Clark RB: Characterization of agonist stimulation of cAMP-dependent protein kinase and G protein-coupled receptor kinase phosphorylation of the β2-adrenergic receptor using phosphoserine-specific antibodies. Mol Pharmacol 2004 ; 65: 196-206.
23. Anderson GP: Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective β2-adrenoceptor agonist bronchodilator. Life Sci 1993 ; 52: 2145-2160.
24. Ball DI, Brittain RT, Coleman RA, Denyer LH, Jack D, Johnson M,, et al. Salmeterol, a novel, long-acting β2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo. Br J Pharmacol 1991 ; 104: 665-671.
25. January B, Seibold A, Allal C, Whaley BS, Knoll BJ, Moore RH,, et al. Salmeterol-induced desensitization, internalization and phosphorylation of the human β2-adrenoceptor. Br J Pharmacol 1998 ; 123: 701-711.